objective(s): as t-cell immunoglobulin and mucin domain 3 (tim-3) is an immune regulatory molecule; its blocking or stimulating could alter the pattern of immune response towards a desired condition. based on the unique features of nanobodies, we aimed to construct an anti-tim-3 nanobody as an appropriate tool for manipulating immune responses for future therapeutic purposes. materials and meth...

Objective(s): As T-cell immunoglobulin and mucin domain 3 (TIM-3) is an immune regulatory molecule; its blocking or stimulating could alter the pattern of immune response towards a desired condition. Based on the unique features of nanobodies, we aimed to construct an anti-TIM-3 nanobody as an appropriate tool for manipulating immune responses for future therapeutic purposes. Materials and Meth...

Central ossifying fibroma is a benign, slow-growing tumor of mesenchymal origin with a predilection for the mandibular premolar and molar areas. The immunophenotype of T cells involved in the antitumor response against this benign tumor is unknown. In this case report, we described a case of a 48-year-old woman presenting with a very large recurrent ossifying fibroma in the mandible, which was ...

Background: T cell Immunoglobulin, Mucin (TIM)-3, is a type I transmembrane glycoprotein belonging to TIM family. This receptor expresses on T helper type 1 (Th1) cells that binds to galectin-9 (Gal9); inducing an inhibitory signal. As a result, apoptosis of Th1 cells occurs and cytotoxicity of CD8 T cells becomes evident in vitro. Therefore, this immunomodulatory molecule may ...

T-cell immunoglobulin and mucin domain 3 (Tim-3) is an immune checkpoint target under investigation in immuno-oncology (IO) trials. Blockade of T-cell-Tim-3 enhances antitumor immunity. Here, we identify additional role for Tim-3 as a growth-suppressive receptor intrinsic to melanoma cells. Inhibition melanoma-Tim-3 by RNA interference promotes, while melanoma-specific overexpression attenuates...

The advent of immune checkpoint therapy revolutionizes the oncology field by achieving durable anti-tumor efficacy and immense clinical progress. Among checkpoints, T cell immunoglobulin mucin domain 3 (TIM-3) has been reported to express on both innate adaptive cells where it accounts for tolerance tumor aggression. It shows promising effects that are applicable in several cancer types. This r...